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IMPORTANCE Steroid 5α-reductase type 3 congenital disorder of glycosylation (SRD5A3-CDG)
is a rare disorder of N-linked glycosylation. Its retinal phenotype is not well described but
could be important for disease recognition because it appears to be a consistent primary
presenting feature.
OBJECTIVE To investigate a series of patients with the samemutation in the SRD5A3 gene and
thereby characterize its retinal manifestations and other associated features.
DESIGN, SETTING AND PARTICIPANTS Seven affected individuals from 4 unrelated families
with early-onset retinal dystrophy as a primary manifestation underwent comprehensive
ophthalmic assessment, including retinal imaging and electrodiagnostic testing.
Developmental and systemic findings were also recorded. Molecular genetic approaches,
including targeted next-generation sequencing, autozygosity mapping, and apexmicroarray,
were tried to reach a diagnosis; all participants were mutation negative. Whole-exome
sequencing or whole-genome sequencing was used to identify the causative variant.
Biochemical profiling was conducted to confirm a CDG type I defect. Patient phenotype data
were collected over the course of ophthalmic follow-up, spanning a period of 20 years,
beginning March 20, 1997, through September 15, 2016.
MAIN OUTCOMES ANDMEASURES Detailed clinical phenotypes as well as genetic and
biochemical results.
RESULTS The cohort consisted of 7 participants (5 females and 2males) whosemean (SD) age
at themost recent examination was 17.1 (3.9) years and whowere all of South Asian ethnicity.
Whole-exome sequencing and whole-genome sequencing identified the same homozygous
SRD5A3 c.57G>A, p.(Trp19Ter) variant as the underlying cause of early-onset retinal dystrophy
in each family. Detailed ocular phenotyping identified early-onset (aged3 years) visual
loss (mean [SD] best-corrected visual acuity, +0.95 [0.34] logMAR [20/180 Snellen]),
childhood-onset nyctalopia, myopia (mean [SD] refractive error, –6.71 [–4.22]), and
nystagmus. Six of the 7 patients had learning difficulties and psychomotor delay. Fundus
autofluorescence imaging and optical coherence tomographic scans were abnormal in all
patients, and electrodiagnostic testing revealed rod and cone dysfunction in the 5 patients
tested.
CONCLUSIONS AND RELEVANCE Mutations in the SRD5A3 genemay cause early-onset retinal
dystrophy, a previously underdescribed feature of the SRD5A3-CDG disorder that is
progressive andmay lead to serious visual impairment. SRD5A3 and other glycosylation
disorder genes should be considered as a cause of retinal dystrophy even when systemic
features are mild. Further delineation of SRD5A3-associated eye phenotypes can help inform
genetic counseling for prognostic estimation of visual loss and disease progression.
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C ongenital disorders of glycosylation (CDGs) are a largegroup of neurometabolic diseases caused by impairedglycoconjugate synthesis. Type I CDGs (CDG-I) result
fromdisruptions in theearlyN-linkedglycosylationpathway.1
NumerousCDG-I subtypes exist that are characterizedbyneu-
rologic, developmental, hepatic, and coagulation abnormali-
ties alongside ocular, muscular, skeletal, dermatologic, car-
diovascular, or genitourinary involvement in some forms.1,2
Approximately 23 different genes have been associated with
this group of disorders.1 Steroid 5α-reductase type 3 (SRD5A3
[OMIM 611715]) encodes a polyprenol reductase enzyme re-
quired for the synthesis of dolichol, the end product of the
mevalonatepathway.3Dolicholundergoesphosphorylation to
producedolichol phosphate that serves as the lipid-anchor for
N-glycan biosynthesis in the endoplasmic reticulum.3
Biallelic mutations in SRD5A3 cause SRD5A3-CDG (for-
merly known as CDG-Iq [OMIM 612379]), a phenotypically
variable form of CDG-I that features nystagmus, optic atro-
phy, visual loss, muscle hypotonia, intellectual disability,
and cerebellar ataxia.3,4 Biochemically, SRD5A3-CDG is char-
acterized by a transferrin isoelectric focusing pattern that is
typical of CDG-I.5 Defective glycan synthesis results in
altered sialotransferrin forms, which are detectable by
charge differences and characterized by increased disialo-
transferrin and/or asialotransferrin in cases of CDG-I.5 Kah-
rizi syndrome (OMIM 612713), featuring iris coloboma, juve-
nile cataract, contractures, kyphosis, mental retardation,
motor delay, and lack of speech, has also been reported in
association with biallelic variants in SRD5A3.6 Patients
described thus far have considerable phenotypic overlap
with SRD5A3-CDG, although they demonstrate a normal
transferrin isoelectric focusing profile.6,7 Unlike other CDG-I
subtypes, all patients with SRD5A3-CDG develop abnormal
ocular phenotypes and almost always experience early-
onset visual loss such that the ocular presentation can be an
early and obvious disease-delineating feature.
Previous studies of this disorder focused on genetic find-
ings associated with the neurometabolic and developmental
manifestations of the condition, with only 1 study acknowl-
edging a retinal abnormality.8 Hence, the appearance, onset,
and progression of the SRD5A3-CDG–related retinal pheno-
type is poorly understood. Our study reports detailed ocular
and developmental phenotypes in 7 individuals, from 4 un-
related familieswithearly-onset retinaldystrophy (EORD)who
harbor thesameSRD5A3mutation,discovered throughwhole-
exomesequencing (WES)orwhole-genomesequencing (WGS).
Methods
Clinical Assessment
Study participants were ascertained fromManchester Centre
for GenomicMedicine, Manchester, England;Moorfields Eye
Hospital, London, England; and St. James’s UniversityHospi-
tal, Leeds, England. The Northwest Research Ethics Commit-
tee grantedapproval for all aspects of this study, and the study
protocol observed the tenets of the Declaration of Helsinki.9
Written informed consentwas obtained from each study par-
ticipant, or parental informed consent was obtained on be-
half of children, as an essential prerequisite for study inclu-
sion. Patient phenotype data were collected over the course
of ophthalmic follow-up, spanning a period of 20 years, be-
ginning March 20, 1997, through September 15, 2016.
Each patient underwent full ophthalmic assessment, in-
cluding visual acuity and dilated fundus examination. Fun-
dus photographs were obtained using conventional 35° color
fundusphotography (TopconGreatBritain) orWidefield color
fundus imaging (Optos plc). Fundus autofluorescence (FAF)
imagingwas conductedusingeither the55°Spectralis (Heidel-
berg Engineering Inc) or ultra-widefield confocal scanning la-
ser imaging (Optos plc). Optical coherence tomography (OCT)
was performed using the Spectralis OCT platform. Five pa-
tients underwent electroretinography, which was performed
using gold-foil electrodes and according to standards speci-
fied by the International Society for Clinical Electrophysiol-
ogy of Vision in 3 patients and using surface electrodes in the
other 2 patients.10,11 Developmental and dysmorphology as-
sessments were conducted by a clinical geneticist (J.C.S.) or
an inherited metabolic disease specialist (S.G.).
Molecular Investigations
Genetic Analysis
Targetednext-generation sequencing (105-gene inherited reti-
nal dystrophy panel testing andWES)was conducted, as pre-
viously detailed by Arno et al.12
The proband of families I and III underwent screening for
a panel of 105 known inherited retinal dystrophy genes (de-
scribed inO’Sullivan et al13) at theManchester GenomicDiag-
nostic Laboratory. Single-nucleotide polymorphism analysis
was performed on family II using an Affymetrix 50k Xba SNP
chip (Affymetrix Inc) on DNA samples from the parents, 1 af-
fected child, and 2 unaffected children to identify regions of
homozygosity in theaffectedchild for theprioritizationof can-
didate genes. Theproband from family IVwas screenedusing
a commercially available APEX microarray (Asper Ophthal-
mics) for 344publisheddisease-causingvariants in8genes as-
sociatedwithLebers congenital amaurosis andEORD.Thepro-
band from families I, II, and III underwentWES as part of the
UK InheritedRetinalDiseaseConsortium, anongoing studyof
Key Points
Question What is the retinal phenotype underlying steroid
5α-reductase type 3 congenital disorder of glycosylation
(SRD5A3-CDG)?
Findings This case series of 7 individuals from 4 unrelated families
with early-onset retinal dystrophy found, through the use of
whole-exome sequencing or whole-genome sequencing, that they
harbored an SRD5A3 c.57G>A, p.(Trp19Ter) homozygous mutation,
whichmanifested through early-onset visual loss, nyctalopia,
myopia, and nystagmus as well as learning difficulties and
psychomotor delay.
Meaning This detailed description of the SRD5A3-CDG retinal
phenotypemay facilitate disease recognition and prognostic
estimation in other cases.
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inherited retinal disease in familieswithout amolecular diag-
nosis following targeted gene panel screening.
The affected individual and unaffected parents of family
IV underwent WGS as part of the 100,000 Genomes Project.
Genomic DNA was processed using a kit (TruSeq DNA PCR-
Free Sample Preparation; Illumina Inc) and sequenced using
a high-throughput sequencing platform (HiSeq X Ten; Illu-
mina Inc), generatingminimumcoverage of 15 times formore
than 97% of the callable autosomal genome. Readings were
aligned tobuildGRCh37of thehumangenomeusinganaligner
(Isaac; Illumina Inc). Single-nucleotidevariants and indels (in-
sertions or deletions) were identified using Platypus soft-
ware (version0.8.1;WellcomeTrust Centre forHumanGenet-
ics) (http://www.well.ox.ac.uk/platypus) andannotatedusing
Cellbasesoftware (https://github.com/opencb/cellbase).Variant
filteringwasperformedusingminorallele frequency inpublicly
available and in-housedata sets, predictedprotein effect, and
familial segregation. Survivingvariantswereprioritizedusing
2 prespecified virtual gene panels from PanelApp (https:
//bioinfo.extge.co.uk/crowdsourcing/PanelApp/): Intellectual
Disability version 1.2, which includes SRD5A3, and Posterior
Segment Abnormalities version 1.7. Allelic state was required
tomatch the curatedmodeof inheritance for variants inpanel
genes.
The SRD5A3 c.57G>A, p.(Trp19Ter) (GenBank NM
_024592) homozygous variant was confirmed by Sanger se-
quencingusingacycle sequencingkit (BigDyeTerminator, ver-
sion 3.1; Applied Biosystems).
Biochemical Studies
Wheresamplesweremadeavailable, type IN-glycosylationde-
fect was confirmed using isoelectric focusing of serum trans-
ferrin and blood coagulation studies.5
Results
Patient Phenotypes
Studyparticipants (5 females and2males)hadamean (SD) age
of 17.1 (3.9) years at theirmost recent examination,were all of
South Asian ethnicity. Phenotypes are summarized in the
Table.
Family I
Family I (G40001), originally from India, had ahistory of con-
sanguinity and no prior family history of health problems.
The proband, patient I-1, from family I was born slightly
underweight at 2.7 kg andwasmildly jaundiced after birth. A
developmental and dysmorphology assessment by a clinical
geneticist found only mild developmental delay. She walked
at age 18 months and developed speech at the normal time.
She attended mainstream school where she received assis-
tance because of her visual problems but was able to com-
plete the same level of work as her peers.
At age 5 weeks, she was not fixing and following but was
otherwisewell. At age 5 years, ophthalmic review identified a
decline in visual acuity; fundus imaging and electrophysi-
ological testing led toapreliminarydiagnosisof congenital sta-
tionarynight blindness (Table andFigure 1AandC). At her lat-
est visit at age 20 years, right and left best-corrected visual
acuitymeasured 1.5 logMAR (20/800Snellen)with amildmy-
opic refractive error (Table). Fundus autofluoresence imaging
was also abnormal (Figure 1B and D).
Patient I-2wasborn at term following anuneventful preg-
nancy andwas otherwise fit andwell. At age 5 years, she was
described as being hyperactive with an attention deficit and
experienced frequent sleep disturbances. At age 7 years, she
wasexaminedbyaclinicalgeneticistwhodiagnosedherashav-
ing social communicationdisorder, behavioral problems, and
learningdifficulties.Dysmorphologyassessment identifiedher
ashaving thickhair; thick gums; coarse facies; and slender, ta-
pered fingers.
At age 2months, she presented withmultiplanar nystag-
mus. On examination, she was found to be mildly myopic,
while fundoscopy revealed only attenuated retinal bloodves-
sels, and electroretinographydemonstratedno recordable re-
sponse in the dark (Figure 1E and G and Table). Fundus auto-
fluoresence at age 3 years was abnormal (Figure 1F andH). At
age 7 years, she began to report symptoms of nyctalopia.
Family II
The proband (II-1) and her affected sister (II-1) from family II
(G15567)wereborn to first-cousinparentsofa familywhoorigi-
nated from India.
Examination of patient II-1 by a clinical geneticist found
she had delayedmotor and speech developmentwith associ-
ated learningdifficulties at ayoungage. Shehadvariablemani-
fest nystagmus and myopia at age 18 months. At age 5 years,
her best-corrected visual acuity measured 3/12 single Kays
(0.60 logMAR[20/80Snellen]) in the rightand left eyes (Table).
Electrodiagnostic testingat age 11years identifiedboth rodand
cone systemdysfunction. Inher seconddecadeof life, shebe-
came symptomatic with nyctalopia and photophobia. Fun-
dus, FAF, and OCT examinations identified multiple abnor-
malities indicative of retinitis pigmentosa (RP) (Table and
Figure 1I-L and Figure 2A and B).
Patient II-2 was examined by a pediatrician at age 18
months and was found to have normal muscle tone but in-
creased,brisk reflexesandmildhyperkeratosison the right leg.
Shealsohaddevelopmental delay and learningdifficulties but
had normal growthmeasurements and a normal skeletal sur-
vey.Shewasparticularlyanxiousandhadaveryshortmemory.
The patient was found to have pendular nystagmus and
rovingeyemovements at age3months.Electrodiagnostic test-
ing at age 7 years suggested rod and cone dysfunction. By age
15 years, her myopia had increased, and she was experienc-
ingpoornightvisionandphotophobia.Results of fundus,FAF,
andOCT examinationswere abnormal and indicative of RP in
the absence of pigmentary changes (Table and Figures 1M-P
and 2C and D).
Family III
Theaffectedsiblingpair fromfamily III (LDS3659)wereborn to
apparentlynonconsanguineousparentsoriginating fromIndia.
Patient III-1 experienced learningdifficulties fromayoung
age and was described as having a slightly “clumsy” walking
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style. Her family noticed she had poor visual behavior within
the first year of life. Amyopic refractive error was detected at
age18months,whichprogressedtohighmyopiabyage16years
(Table). Examinationof the fundus, by color andFAF imaging,
revealed abnormalities suggestive of retinal pigment epithe-
liummalfunction (Table and Figure 1T). The OCT scans were
Table. Ophthalmic and Phenotypic Presentations of PatientsWith SRD5A3 c.57G>A, p.(Trp19Ter) Mutation
Characteristic
Individual/Sex/Family ID
I-1/F/G40001.1 I-2/F/G40001.2 II-1/F/G15567.1 II-2/F/G15567.2 III-1/F/LDS3659.1
III-2/M/
LDS3659.2 IV-1/M/G15063
Demographic Characteristics
Ethnicity South Asian South Asian Indian Indian Pakistani Pakistani Indian
Age at onset 5 wk 2 mo 18 mo 3 mo <1 y 2-3 y <1 y
Age at last
examination, y
20 13 18.5 14.5 16 14 24
Consanguinity + + + + + − -
Ophthalmic Findings
Ophthalmic
history
Failure to fix and
follow, multiplanar
nystagmus, mild
myopia from 2 mo,
nyctalopia from
6 y, initial
diagnosis of CSNB
made at 6 y
Multiplanar
nystagmus,
strabismus,
progressive
myopia from 2 mo,
nyctalopia from
7 y
Variable manifest
nystagmus, squint,
myopia from
18 mo
Nystagmus and
roving eye
movements from
3 mo, myopia,
poor night vision
and photophobia
Roving eye
movements and
nyctalopia from
<1 y, high myopia,
exophoria
decompensating
into an exotropia
from 16 y, central
scotomata
Roving eye
movements from
2-3 y, nyctalopia,
high myopia,
exophoria
Early-onset
nystagmus and
myopia
BCVA (Snellen
equivalent)
[age, y]
1.5 logMAR
(20/640) OU [20]
1.3 logMAR
(20/400) OU [7];
1.04 logMAR
(20/250) OD ;
1.20 logMAR
(20/320) OS [13]
0.900 Crowded
logMAR (20/160)
OD;
0.800 (20/125)
crowded logMAR
OS [6]; 0.72
logMAR (20/100)
OD; 0.36 logMAR
(20/50) OS [18.5]
1.0 logMAR
(20/200) OD; 0.8
logMAR (20/125)
OS [15]
NA NA 0.6 logMAR
(20/80) OU [4.5];
1.0 logMAR
(20/200) OU
[24 y]
Refractive
error (age)
−1.00/+0.25 × 90
OD;
−1.25/+0.25 × 80
OS (20 y)
−2.00/+1.00
× 100 OD;
−3.00/+1.00 × 80
OS (2 mo);
−6.00/+1.75 × 90
OD and
−6.50/+1.00 × 90
OS (3 y)
−2.5/−2.5 × 180
OD;
−1.5/−3.0 × 170
OS (6 y);
−3.00/−3.5 × 180
OD;
−3.50/−4.0 × 160
OS (18.5 y)
−1.5/−1.25 × 180
OD;
−2.00/−2.00
× 180 OS (18 mo);
−5.5/−3.75 × 155
OD;
−5.5/−3.75 × 100
OS (15 y)
−15.50/+0.25
× 109 OD;
−14.00/
+1.00 × 92 OS
(16 y)
−9.50/+1.50
× 103 OD,
−8.25/+2.5 × 106
OS (14 y)
OD:
−7.00/−0.75
× 180; OS: −7.5
DS (24 y)
Fundus
imaging
Optic disc pallor,
foveal hypoplasia,
granular
appearance of
peripheral retina,
attenuated retinal
vasculature
Subtle temporal
optic disc pallor,
mildly attenuated
retinal arterioles,
prominent nerve
fiber layer visibly
radiating around
the superior and
inferior vascular
arcades; patchy
(RE) and stippled
(LE) macular
reflex
Tilted optic disc
with temporal
pallor,
peripapillary
atrophy
temporally,
absence of foveal
reflex (LE only),
attenuated retinal
vasculature
Myopic tilted discs,
attenuated retinal
vasculature, subtle
mottling in the
retinal periphery
Myopic tilted discs,
attenuated retinal
vasculature, subtle
mottling in the
retinal periphery
Myopic tilted discs,
attenuated retinal
vasculature, subtle
mottling in the
retinal periphery
Optic disc pallor,
attenuated
retinal
vasculature
FAF Well-defined
ring of
hyperautofluores-
cence around the
macula
Well-defined
ring of
hyperautofluores-
cence around the
macula
Well-defined
ring of
hyperautofluores-
cence around the
macula
Diffuse ring of
hyperautofluores-
cence around the
macula
Diffuse ring of
hyperautofluores-
cence around the
macula
Well-defined
ring of
hyperautofluores-
cence around the
macula
Diffuse ring of
hyperautofluores-
cence around the
macula
OCT Data not available Data not available Widespread loss
of outer retinal
structures with
relative
preservation of
foveal structures,
including
photoreceptors
Widespread loss
of outer retinal
structures with
relative
preservation of
foveal structures,
including
photoreceptors
Widespread loss
of outer retinal
structures and
complete absence
of the
photoreceptor
layer
Widespread loss
of outer retinal
structures with
relative
preservation of
foveal structures,
including
photoreceptors
Widespread loss
of outer retinal
structures with
relative
preservation of
foveal structures,
including
photoreceptors
ERG (age
at testing)
Indicative of
rod-cone
dystrophy (no
details available)
(5 y)
Low-amplitude
light-adapted
response,
extinguished
dark-adapted
response (2 mo)
Undetectable
rod-specific
responses, delayed
and subnormal
cone-specific
responses (11 y)
Limited
compliance with
test but reduced
and delayed
cone-specific
responses found
with rod
involvement
NA NA Profoundly
electronegative
ERG, grossly
delayed
cone-specific
responses
(continued)
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corroborative of this finding and indicated loss of outer seg-
ment structureswith complete loss of thephotoreceptor layer
(Figure 2E).
Patient III-2, when examined at age 14 years, was found
to have an ataxic gait and reduced upper-limb coordination,
bothofwhichare signsofmildcerebellardisease.Healsodem-
onstrated global developmental delay andexperienced recur-
rent respiratory tract infections.
He experienced loss of vision with associated roving eye
movementsbetweenages2and3years.Healsopresentedwith
early-onset nyctalopia and high myopia (Table). Ophthalmic
examination revealed abnormalities similar to those of his
brother, apart from a small region of photoreceptor preserva-
tion within the central macula (Table and Figure 2F).
Family IV
The proband (IV-1) from family IV (G15063), a male, was
born to apparently nonconsanguineous parents originating
from India. Examination of patient IV-1 at age 4½ years iden-
tified developmental delay, learning difficulties, and abnor-
mal curvature of the spine (Table). His ophthalmic history
revealed infantile-onset nystagmus and reduced vision. At
age 4½ years, he was found to have reduced visual acuity
(0.60 logMAR OU [20/80 Snellen]) and myopia (Table). At
his most recent examination at age 24 years, his vision had
deteriorated (Table), and fundus examination revealed reti-
nal vessel attenuation and pale optic discs (Figure 1Q and S).
Electroretinography indicated both rod and cone dysfunc-
tion (Table), and an OCT scan revealed loss of outer segment
structures with relative preservation of the central macula,
bilaterally (Figure 2G and H).
Molecular Analysis
Clinically available genetic testing did not identify any
potentially pathogenic variants in 105 known retinal dystro-
phy genes in the proband of families I and III. Autozygosity
mapping and candidate gene sequencing did not identify
any pathogenic variants in the proband of family II. Apex
array analysis in patient IV-1 was also mutation negative.
Subsequent WES or WGS led to the identification of SRD5A3
c.57G>A, p.(Trp19Ter) homozygous variant in each proband.
Sanger sequencing confirmed the presence and zygosity of
this variant in every affected member of each family. The
SRD5A3 c.57G>A, p.(Trp19Ter) variant has an allele fre-
quency of 0.001174 in 4684 control individuals of South
Asian ethnicity, according to the Exome Aggregation Consor-
tium data set (http://exac.broadinstitute.org/). In the
homozygous state, this samevarianthasbeendescribedas the
cause of SRD5A3-CDG in 4 unrelated families.4,8,14
Both siblings from family III underwent screening for bio-
chemical abnormalities thatmaybeassociatedwithCDG.5Mild
abnormalities of blood clotting (activated partial thrombo-
plastin time [aPTT], 43.6 seconds; aPTT ratio, 1.4 [interna-
tional normalized ratio, 3.23]) and amicrocytic hypochromic
blood profile were observed in both. Liver function test re-
sults were normal; however, a CDG type I pattern of transfer-
rin glycoforms was observed.
Discussion
Biallelic mutations in SRD5A3 are associated with SRD5A3-
CDG, aphenotypically variabledisorder ofN-linkedglycosyla-
Table. Ophthalmic and Phenotypic Presentations of PatientsWith SRD5A3 c.57G>A, p.(Trp19Ter) Mutation (continued)
Characteristic
Individual/Sex/Family ID
I-1/F/G40001.1 I-2/F/G40001.2 II-1/F/G15567.1 II-2/F/G15567.2 III-1/F/LDS3659.1
III-2/M/
LDS3659.2 IV-1/M/G15063
Developmental/
neurological
findings
Mild
developmental
delay up to age 5 y
Dysmorphic,
communication
and behavioral
problems, learning
difficulties,
recurrent
respiratory
infections, gait
ataxia
Psychomotor
delay, learning
difficulties
Increased brisk
reflexes,
psychomotor
delay, and learning
difficulties
Learning
difficulties, gait
ataxia, normal
reflexes, mild
upper-limb
coordination
difficulties on
finger-nose test;
normal height,
weight, and head
circumference
Learning
difficulties,
developmental
delay, gait ataxia,
normal reflexes,
mild upper-limb
coordination
difficulties on
finger-nose test;
recurrent
respiratory
infections; normal
height, weight,
and head
circumference
Developmental
delay, learning
difficulties,
scoliosis
Other
investigations
Normal urine
organic acid and
plasma phytanic
acid levels
Normal hearing
assessment results;
normal values for
uMPS,
oligosaccharides,
and lysosomal
enzymes; normal
radiographic
findings and aCGH
results
Normal values for
VLCFAs, lysosomal
enzymes, and
white cell and
plasma enzymes
Normal values for
VLCFAs, lysosomal
enzymes, and
white cell and
plasma enzymes
Abbreviations: aCGH, array comparative genomic hybridization; DS, diopter
sphere; ERG, electroretinography; FAF, fundus autofluoresence; NA, not
available; OCT, optical coherence tomography; OD, right eye; OS, left eye;
OU, both eyes; uMPS, urine mucoplysaccharides; VLCFAs, very long-chain fatty
acids; +, present; −, absent.
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tion that isnormally characterizedbyneurodevelopmental ab-
normalities and ophthalmic manifestations.3,4 We describe 7
patients from4 familieswith a retinopathy consequent on the
SRD5A3 c.57G>A, p.(Trp19Ter) mutation. This mutation has
been reportedpreviously to cause SRD5A3-CDG in4otherun-
related families.4,8,14
Ourcaseseriesprovidesan in-depthdescriptionof theocu-
lar symptomologyandappearanceover the courseof ophthal-
mic follow-up. The retinopathy, unlike the extraocular fea-
tures of this disease, appears to be slowly progressive. On
fundal view, signs of retinal disease may be subtle and bone
spicules may be absent in young patients. Similarly, syn-
dromicmanifestations associatedwithSRD5A3mutationmay
also be mild. This detailed description of retinal phenotype
couldbe important for earlydisease recognitionbecause it ap-
pears to be a consistent primary presenting feature. Early-
onset visual loss (≤3 years of age;mean [SD] best-correctedvi-
sual acuity, +0.95 [0.34] logMAR [20/180 Snellen]) and
Figure 1. Color Fundus and Fundus Autofluorescence Images of PatientsWith SRD5A3 c.57G>A, p.(Trp19Ter)
Variant
Color RE FAF RE FAF LEColor LE
A B DC
Patient I-1 20 y Patient I-1 20 y Patient I-1 20 y Patient I-1 20 y
E F HG
Patient I-2 13 y Patient I-2 13 y Patient I-2 13 y Patient I-2 13 y
M N PO
Patient II-2 12 y Patient II-2 12 y Patient II-2 12 y Patient II-2 12 y
Q R TS
Patient IV-1 24 y Patient IV-1 24 y Patient IV-1 24 y Patient IV-1 16 y
I J LK
Patient II-1 17 y Patient II-1 17 y Patient II-1 17 y Patient II-1 17 y
A, C, E, and G, Widefield color fundus
imaging (Optos plc). I, K, M, O, Q, and
S, 35° Color fundus photography.
B, D, F, H, J, L, N, P, R, and T, fundus
autofluorescence imaging.
LE indicates left eye; RE, right eye;
arrows, foveal autofluorescence/
hypoplasia; arrowheads, optic disc
pallor; and asterisks, vessel
attenuation.
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nystagmus are consistentmanifestations associatedwith the
SRD5A3 c.57G>A, p.(Trp19Ter) variant in this cohort of 7 pa-
tients. Other shared ocular findingswere retinal arteriolar at-
tenuation in the absence of bone spicule formation (n = 7),
childhood-onsetnyctalopia (n = 5), andopticdiscpallor (n = 5).
In addition, each of the patients described in this series expe-
riencedvaryingdegrees of progressivemyopia (mean [SD] re-
fractiveerror, –6.71 [–4.22]), ranging fromrelativelymild tohigh
(Table). None of the patients were microphthalmic, and they
did not have ocular colobomata as has been described in as-
sociationwithotherSRD5A3mutations.4Mutual systemic as-
sociations included learningdifficultiesanddevelopmentalde-
lay. One patient was found to have only mild developmental
delay as a young child (<5 years),whichmayhave been attrib-
utable to her severe visual impairment because she went on
tomeetnormaldevelopmentaland intellectualmilestoneswith
increasing age.
Despite the absence of a pigmentary retinopathy, wide-
spread loss of outer retinal structures was evidenced by OCT,
with relative preservation of foveal photoreceptors and only
mild epiretinal membrane formation (Figure 2A-H). Electro-
retinography, when performed (n = 5), identified dysfunc-
tion in both rod and cone pathways at the level of the photo-
receptor, allowingdiscrimination fromdisorders involving the
photoreceptor-bipolar cell synapse, such as congenital sta-
tionary night blindness, as 3 of the 7 patients initially re-
ceiveda clinical diagnosis of congenital stationarynightblind-
ness.Previous reportsofpatientswithSRD5A3mutationshave
not described OCT findings. There has been a single descrip-
tion of retinal bone spicule pigmentation in an adult sibling
pair with the SRD5A3 c.57G>A, p.(Trp19Ter) variant. Because
of the lack of previous descriptions of RP as a feature of
SRD5A3-CDG,Kara andcolleagues8hypothesized thatRPmay
be a late-onset feature of the condition. Our findings suggest
that theonset of retinal degeneration is likely tooccur in child-
hood in at least a proportionof cases. Ocular imaging andFAF
suggest early dysfunction of the retinal pigment epithelium.
Rhodopsin is apigment-containing,Gprotein–coupled re-
ceptor that is expressed in rod photoreceptors cells, where it
specifically localizes to the rodouter segments.15 Studieshave
shown that the N-terminus of rhodopsin contains 2 N-linked
glycosylation sequences.16 Mutations at glycosylated amino
acid residues or surrounding glycosylation consensus se-
quences of rhodopsin cause autosomal dominant and secto-
ralRP inhumans.17,18 Studies inanimalmodelsexpressingnon-
glycosylated rhodopsinhave shownthat, although themutant
proteins undergo normal biosynthesis, folding, and traffick-
ing, they confer toxicity,which causes rod cell death and leads
Figure 2. Optical Coherence Tomography in PatientsWith SRD5A3 c.57G>A, p.(Trp19Ter) Variant
Patient II-1 RE, 17 yA Patient II-1 LE, 17 yB
Patient IV-1 RE, 24 yG Patient IV-1 LE, 24 yH
Patient III-1 RE, 14 yE Patient III-2 RE, 12 yF
Patient II-2 RE, 12 yC Patient II-2 LE, 12 yD
Optical coherence tomographic scans
shown as horizontal (A through E, G,
and H) or vertical (F) scans and
accompanying en face infrared image
with location at which the scan
through themacula was taken
(indicated by green line). Arrowheads
demarcate the transition of absent or
present photoreceptors (except in C,
where part of themacula is not
visible, and in E, where the
photoreceptor layer is completely
absent). LE indicates left eye;
RE, right eye.
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to light-sensitive retinal degeneration.19 Evidence ofwhether
nonglycosylated rhodopsin incorporates intoand initiatesdisc
morphogenesis in rod outer segments is conflicting.20,21 It is
possible that the SRD5A3 c.57G>A, p.(Trp19Ter) variant pre-
ventsnormal glycosylationof rhodopsin in the retina and sub-
sequently impairs its normal incorporation and/or function in
the rod outer segments, thereby leading to defective photo-
transduction and loss of vision before the eventual photore-
ceptor death and the presentation of RP. Similarly, nonglyco-
sylation of other retinal proteins, such as ABCA4, known to
have 7N-glycosylation sites, could also lead to defective pho-
totransduction and eventual cell death.22 This is an area that
warrants further research.
TheSRD5A3c.57G>A,p.(Trp19Ter)varianthasanallele fre-
quency of 0.0012 in the South Asian population according to
the Exome Aggregation Consortium data set. This frequency
is 30 timeshigher than forother ethnic groups, suggesting that
SRD5A3 c.57G>A, p.(Trp19Ter) is an ancestral variant within
this specificpopulation.Further, findings fromourcohort sug-
gest that phenotypic subtleties mean this condition goes un-
recognizedorunsuspected.Alongsiderecentevidenceforarole
of other glycosylation disorder genes in nonsyndromic reti-
naldystrophy(POMGNT123andDHDDS24),wesuggest thatCDG
genes be considered in clinical diagnostic genepanels for reti-
nal disease.
Limitations
For someof the families described in this study, parental DNA
samples were unavailable to confirm zygosity of the SRD5A3
c.57G>A, p.(Trp19Ter) homozygous variant identified in each
affected familymember. Therefore,wecannotdefinitively ex-
clude thepossibilityof aheterozygousdeletionon1allele. Fur-
thermore, becauseof the limited informationavailable regard-
ingeachfamilypedigree,wecannotexclude thepossibility that
each of the 5 families described here shares a distant, com-
mon ancestor.
Conclusions
This case series provides a detailed account of the retinal dys-
trophy consequent on the SRD5A3 c.57G>A, p.(Trp19Ter)mu-
tation, delineating the complex phenotype associated with
SRD5A3-CDG. Furthermore, we illustrate thewide variability
in onset and progression of the disorder in patients with the
same null mutation. We report EORD as a novel feature of
SRD5A3-CDG and suggest that retinal degeneration without
pigmentary changemaybe anearlymanifestationofCDG that
may progress to RP over time. Of note, our findings also sug-
gest thatSRD5A3maycause theseocularmanifestationsalong-
side mild learning difficulties in some instances, in contrast
to the neurodevelopmental delay and other systemic fea-
tures usually associatedwith SRD5A3-CDG.3,4 Ourwork adds
to cumulative evidence that next-generation sequencing of-
fers aproficientmeansofdiagnosis for this geneticallyhetero-
geneousandphenotypicallyvariablegroupofconditions.6,25,26
For CDG, precise diagnosis enables the provision of more ac-
curateprognostic information regarding loss of visionand risk
of later-onset manifestations. Better understanding of the
pathogenesis of SRD5A3-mediated retinal disease could lead
to the development of novel therapeutic strategies. Findings
in our cohort show that themacula, although nonfunctional,
remains structurally intact, potentially contributing to mak-
ing this condition a good target for gene therapy.
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